You are on our international English website. This site features our entire product portfolio worldwide. The products featured may not be available in the US. If you are a citizen from the US, please visit your country website for local information and contacts.
Medical Technology for healthcare professionals
Global website (English)
back
Medical Technology
recommended searches
popular searches
CIRRUS 6000

CIRRUS OCT

AMD & Geographic Atrophy Tool Kit

Give your patients every opportunity to access the exciting new era of AMD treatment and care with Advanced RPE Analysis and ZEISS AngioPlex, the AMD & Geographic Atrophy Tool Kit from ZEISS CIRRUS.

Contact Us

  • Third-party Content Blocked

    The video player is blocked due to your cookie preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

Age-related macular degeneration (AMD) is the leading cause of severe, irreversible vision loss in people over age 60, and it is growing at an alarming rate all over the world. Your patients may be at risk. It is estimated that 196 million people had AMD in 2020, with that number rising to 288 million by 2040, yet 25% of AMD in the primary eyecare setting goes undiagnosed.1,2 That's over 46% increase - 92 million more people who may be at risk of losing their vision, and they have no idea it’s even happening. We can help them. Learn how to utilize Advanced RPE Analysis and AngioPlex® together as an AMD and Geographic Atrophy Tool Kit for the diagnosis and management of your AMD patients.

It is estimated that 196 million people worldwide had AMD in 2020.

AMD affects central vision and 92 million more people may be at risk of sight loss.

Adults age 60+ are at a higher risk for developing AMD.

Smoking, family history, unhealthy diet, inactivity and exposure to sunlight are some of the risk factors for developing AMD.

A new era in geographic atrophy

The role of OCT
Advanced RPE Analysis

Advanced RPE Analysis

Quantitative measurement and historical data comparison

The Advanced RPE Analysis, available on the ZEISS CIRRUS OCT, was specifically created to help clinicians manage non-neovascular AMD in all its forms.

AngioPlex

AngioPlex

Importance of early progression detection

OCT angiography (OCTA) systems such as the ZEISS CIRRUS AngioPlex®, continue to push the boundaries of ocular imaging so that clinicians can better care for these patients.

A collaborative care model

A collaborative care model

Optimizing patient outcomes

The ZEISS CIRRUS OCT with its Advanced RPE Analysis and AngioPlex® can provide the foundation on which optometrists and ophthalmologists can detect and monitor all forms of AMD.

Downloads

Get in touch with us!

Receive more information about the product and availability in your country!

Form is loading...

Personal contact information

If you want to have more information on data processing at ZEISS please refer to our data privacy notice. 

Available services

ZEISS OPTIME Service Plans

Enabling you to focus on patient care.

Make a sales request

Any questions about buying our products?

Click here

to get direct assistance from our service team.

Stay up to date

Sign up for updates on current topics, news and events.
  • 1

    Wong, Wan Ling, et al. "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis." The Lancet Global Health 2.2 (2014): e106-e116
  • 2

    Neely DC, Bray KJ, Huisingh CE, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017;135(6):570-5